RNAi therapeutics for CNS disorders

被引:35
|
作者
Boudreau, Ryan L. [1 ]
Davidson, Beverly L. [1 ,2 ]
机构
[1] Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA
[2] Univ Iowa, Dept Neurol, Iowa City, IA 52242 USA
关键词
RNAi; Therapy; Neurodegenerative; Huntington's; Alzheimer's; Parkinson's; Ataxias; DOUBLE-STRANDED-RNA; SMALL INTERFERING RNA; POLYGLUTAMINE-INDUCED NEURODEGENERATION; HUNTINGTONS-DISEASE; ALPHA-SYNUCLEIN; ALZHEIMERS-DISEASE; PROLONGS SURVIVAL; MUTANT SOD1; TRANSGENIC MICE; GENE-EXPRESSION;
D O I
10.1016/j.brainres.2010.03.038
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
RNA interference (RNAi) is a process of sequence-specific gene silencing and serves as a powerful molecular tool to manipulate gene expression in vitro and in vivo. RNAi technologies have been applied to study gene function and validate drug targets. Researchers are investigating RNAi-based compounds as novel therapeutics to treat a variety of human diseases that are currently lacking sufficient treatment. To date, numerous studies support that RNAi therapeutics can improve disease phenotypes in various rodent models of human disease. Here, we focus on the development of RNAi-based therapies aimed at treating neurological disorders for which reduction of mutant or toxic gene expression may provide clinical benefit. We review RNAi-based gene-silencing strategies, proof-of-concept studies testing therapeutic RNAi for CNS disorders, and highlight the most recent research aimed at transitioning RNAi-based therapeutics toward clinical trials. (C) 2010 Elsevier B.V. All rights reserved.
引用
收藏
页码:112 / 121
页数:10
相关论文
共 50 条
  • [21] Delivery of RNAi therapeutics: work in progress
    Miller, Andrew D.
    EXPERT REVIEW OF MEDICAL DEVICES, 2013, 10 (06) : 781 - 811
  • [22] The Growing Class of Novel RNAi Therapeutics
    Traber, Gavin M.
    Yu, Ai-Ming
    MOLECULAR PHARMACOLOGY, 2024, 106 (01) : 13 - 20
  • [23] RNAi therapeutics: Principles, prospects and challenges
    Aagaard, Lars
    Rossi, John J.
    ADVANCED DRUG DELIVERY REVIEWS, 2007, 59 (2-3) : 75 - 86
  • [24] Chemical and structural modifications of RNAi therapeutics
    Ku, Sook Hee
    Jo, Sung Duk
    Lee, Yeon Kyung
    Kim, Kwangmeyung
    Kim, Sun Hwa
    ADVANCED DRUG DELIVERY REVIEWS, 2016, 104 : 16 - 28
  • [25] RNAi agents as chikungunya virus therapeutics
    Parashar, Deepti
    Cherian, Sarah
    FUTURE VIROLOGY, 2016, 11 (05) : 321 - 329
  • [26] RNAi therapeutics for the treatment of liver diseases
    Akinc, Akin
    Anderson, Daniel
    Bramlage, Birgit
    Bumcrot, David
    Dorkin, J. Robert
    Fitzgerald, Kevin
    Frank-Kamenetsky, Maria
    Goldberg, Michael
    Harborth, Jens
    Horton, Jay D.
    Jayaprakash, K. Narayanannair
    Jayaraman, Muthusamy
    John, Matthias
    Rajeev, Kallanthottathil
    Kotelianski, Victor
    Langer, Robert
    Manoharan, Muthiah
    Nechev, Lubomir
    Qin, June
    Racie, Timothy
    Roehl, Ingo
    Sah, Dinah
    Soutschek, Jurgen
    Vornlocher, Hans-Peter
    Zimmermann, Tracy
    Zumbuehl, Andreas
    HEPATOLOGY, 2007, 46 (04) : 800A - 800A
  • [27] A modular platform for targeted RNAi therapeutics
    Kedmi, Ranit
    Veiga, Nuphar
    Ramishetti, Srinivas
    Goldsmith, Meir
    Rosenblum, Daniel
    Dammes, Niels
    Hazan-Halevy, Inbal
    Nahary, Limor
    Leviatan-Ben-Arye, Shani
    Harlev, Michael
    Behlke, Mark
    Benhar, Itai
    Lieberman, Judy
    Peer, Dan
    NATURE NANOTECHNOLOGY, 2018, 13 (03) : 214 - +
  • [28] A modular platform for targeted RNAi therapeutics
    Ranit Kedmi
    Nuphar Veiga
    Srinivas Ramishetti
    Meir Goldsmith
    Daniel Rosenblum
    Niels Dammes
    Inbal Hazan-Halevy
    Limor Nahary
    Shani Leviatan-Ben-Arye
    Michael Harlev
    Mark Behlke
    Itai Benhar
    Judy Lieberman
    Dan Peer
    Nature Nanotechnology, 2018, 13 : 214 - 219
  • [29] RNAi therapeutics: SNALPing siRNAs in vivo
    J J Rossi
    Gene Therapy, 2006, 13 : 583 - 584
  • [30] Biomaterials in RNAi therapeutics: quo vadis?
    Wagner, Ernst
    BIOMATERIALS SCIENCE, 2013, 1 (08) : 804 - 809